MBX Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from MBX Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-56.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 74% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-464.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 97% of Healthcare companies in United States.
Cash Cushion Ratio
+16%Cash, after subtracting all debt, equals 16% of its market value (net cash).
Higher than 59% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
MBX Biosciences, Inc. made a loss over the last year. MBX Biosciences, Inc. owes $0.06 for every $1 it owns. MBX Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMBX Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.70The share price is 5.70 times MBX Biosciences, Inc.'s book value per share, higher than 75% of Healthcare companies in United States.
Market cap
$2.3 BThe total market value of all of MBX Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 78% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$410 MWhat MBX Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.50Net worth divided by the number of shares. The share price of $48.50 is 5.7 times this, which is the P/B above.
Return on equity (ROE)
-33.2%MBX Biosciences, Inc. lost 33.2% of its shareholders' money over the last year, higher than 59% of Healthcare companies in United States.
Owes vs Owns
0.06×MBX Biosciences, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Dividend yield
NoneMBX Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossMBX Biosciences, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashMBX Biosciences, Inc. held $373 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For MBX Biosciences, Inc.: $2.3 B ÷ $410 M (30 Jun 2026) = 5.7.
What is MBX Biosciences, Inc.'s return on equity?
MBX Biosciences, Inc. lost 33.2% of its shareholders' money over the last year, higher than 59% of Healthcare companies in United States.
How much does MBX Biosciences, Inc. owe compared with what it owns?
MBX Biosciences, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Does MBX Biosciences, Inc. pay a dividend?
No. MBX Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.